ATE533770T1 - PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS - Google Patents

PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS

Info

Publication number
ATE533770T1
ATE533770T1 AT06816408T AT06816408T ATE533770T1 AT E533770 T1 ATE533770 T1 AT E533770T1 AT 06816408 T AT06816408 T AT 06816408T AT 06816408 T AT06816408 T AT 06816408T AT E533770 T1 ATE533770 T1 AT E533770T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidines
protein kinase
kinase inhibitors
inhibitors
protein
Prior art date
Application number
AT06816408T
Other languages
German (de)
Inventor
Kamil Paruch
Timothy Guzi
Michael Dwyer
Carmen Alvarez
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE533770T1 publication Critical patent/ATE533770T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
AT06816408T 2005-10-06 2006-10-04 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS ATE533770T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72419705P 2005-10-06 2005-10-06
PCT/US2006/039136 WO2007041712A1 (en) 2005-10-06 2006-10-04 Pyrazolopyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE533770T1 true ATE533770T1 (en) 2011-12-15

Family

ID=37560916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816408T ATE533770T1 (en) 2005-10-06 2006-10-04 PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS

Country Status (18)

Country Link
US (1) US7776865B2 (en)
EP (1) EP1931676B1 (en)
JP (2) JP5052518B2 (en)
KR (1) KR20080063806A (en)
CN (1) CN101321760A (en)
AR (1) AR056206A1 (en)
AT (1) ATE533770T1 (en)
AU (1) AU2006299338A1 (en)
BR (1) BRPI0617150A2 (en)
CA (1) CA2624882C (en)
EC (1) ECSP088350A (en)
IL (1) IL190598A0 (en)
NO (1) NO20082092L (en)
PE (1) PE20070543A1 (en)
RU (1) RU2008117298A (en)
TW (1) TW200745123A (en)
WO (1) WO2007041712A1 (en)
ZA (1) ZA200802995B (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1931676B1 (en) * 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
WO2007044441A2 (en) * 2005-10-06 2007-04-19 Schering Corporation Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
MX2008011430A (en) * 2006-03-08 2008-09-18 Novartis Ag Use of pyrazolo[1,5a]pyrimidin-7-yl amine derivatives in the treatment of neurological disorders.
EP2027127A1 (en) * 2006-05-22 2009-02-25 Shering Corporation Pyrazolo [1, 5-a]pyrimidines as cdk inhibitors
ES2403546T3 (en) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Bruton tyrosine kinase activity probe and method of use
KR101546493B1 (en) * 2006-11-06 2015-08-21 톨레로 파마수티컬스, 인크. [12-] [15-] Imidazo[12-B]pyridazine and pyrazolo[15-A]pyrimidine derivatives and their use as protein kinase inhibitors
TW200845962A (en) 2007-05-08 2008-12-01 Schering Corp Methods of treatment using intravenous formulations comprising temozolomide
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
ES2372559T3 (en) * 2007-05-09 2012-01-23 Abbott Laboratories HETEROCYCLIC COMPOUNDS CONDENSED AS PROTEIN QUINASE INHIBITORS.
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2009004329A1 (en) * 2007-07-02 2009-01-08 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors
CA2705092A1 (en) * 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2011519973A (en) * 2008-05-12 2011-07-14 アムネスティックス・インコーポレーテッド Information about compound-related applications to improve learning and memory
CL2009001152A1 (en) 2008-05-13 2009-10-16 Array Biopharma Inc Compounds derived from n- (4- (nitrogen cycloalkyl-1-yl) -1h-pyrrolo [2,3-b] pyridin-3-yl) amide, kinase inhibitors; Preparation process; pharmaceutical composition; and its use for the treatment of a proliferative disease.
PA8851101A1 (en) * 2008-12-16 2010-07-27 Lilly Co Eli AMINO PIRAZOL COMPOUND
US8957064B2 (en) * 2009-02-13 2015-02-17 Bayer Intellectual Property Gmbh Fused pyrimidines
EP2413932A4 (en) * 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibitors of akt activity
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8993535B2 (en) 2009-09-04 2015-03-31 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
AR079234A1 (en) * 2009-12-01 2012-01-04 Abbott Lab NITROGEN CONDENSED HETEROCICLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT ONCOLOGICAL AFFECTIONS, THE NERVOUS SYSTEM AND / OR THE IMMUNE SYSTEM.
WO2012007416A1 (en) * 2010-07-13 2012-01-19 Bayer Pharma Aktiengesellschaft Bicyclic pyrimidines
WO2012013713A2 (en) * 2010-07-28 2012-02-02 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-b]pyridazines
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2834093T3 (en) 2011-07-21 2021-06-16 Sumitomo Dainippon Pharma Oncology Inc Heterocyclic protein kinase inhibitors
CA2849566C (en) 2011-11-09 2021-02-09 Cancer Research Technology Limited 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use
ES2589955T3 (en) * 2012-01-10 2016-11-17 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
EP2855448B1 (en) 2012-05-15 2017-02-08 Cancer Research Technology Ltd 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof
PL3808749T3 (en) 2012-12-07 2023-07-10 Vertex Pharmaceuticals Incorporated Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
PL3023100T3 (en) 2013-07-18 2019-07-31 Taiho Pharmaceutical Co., Ltd. Antitumor drug for intermittent administration of fgfr inhibitor
US10124003B2 (en) 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
PE20160532A1 (en) 2013-08-23 2016-05-21 Incyte Corp COMPOUND OF FURO CARBOXAMIDE AND TENOPYRIDINE USEFUL AS INHIBITORS OF PIM KINASES
JP6543252B2 (en) 2013-12-06 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 2-Amino-6-fluoro-N- [5-fluoro-pyridin-3-yl] pyrazolo [1,5-a] pyrimidine-3-carboxamide compounds useful as ATR kinase inhibitors, their preparation, their different solid forms And radiolabeled derivatives
MX2016015874A (en) 2014-06-05 2017-03-27 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
PT3157566T (en) 2014-06-17 2019-07-11 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
WO2016011019A1 (en) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
TW201702218A (en) 2014-12-12 2017-01-16 美國杰克森實驗室 Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
AU2016240841C1 (en) 2015-03-31 2018-05-17 Taiho Pharmaceutical Co., Ltd. Crystal of 3,5-disubstituted benzene alkynyl compound
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (en) 2015-09-09 2021-08-01 美商英塞特公司 Salts of a pim kinase inhibitor
CA3000684A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
TW201718546A (en) 2015-10-02 2017-06-01 英塞特公司 Heterocyclic compounds useful as PIM kinase inhibitors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
KR20240014585A (en) 2016-03-04 2024-02-01 다이호야쿠힌고교 가부시키가이샤 Preparation and composition for treatment of malignant tumors
TW201902896A (en) * 2017-05-22 2019-01-16 瑞士商赫孚孟拉羅股份公司 Therapeutic compounds and compositions and methods of use thereof
JP7216705B2 (en) * 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitors and methods of use thereof
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
CN117838695A (en) 2018-04-13 2024-04-09 住友制药肿瘤公司 PIM kinase inhibitors for the treatment of myeloproliferative neoplasms and cancer-related fibrosis
CN108586341B (en) * 2018-05-25 2020-05-08 天津商业大学 Amide compounds and medicinal salts thereof, and preparation method and medicinal application thereof
AU2019360941A1 (en) * 2018-10-15 2021-04-29 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
CN109293630A (en) * 2018-11-15 2019-02-01 山东大学 Compound of class containing substituted pyrazolecarboxylic and the preparation method and application thereof
CN113412262A (en) 2019-02-12 2021-09-17 大日本住友制药肿瘤公司 Formulations comprising heterocyclic protein kinase inhibitors
CN112457306A (en) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3, 5-disubstituted pyrazole compounds as kinase inhibitors and application thereof
CN114957261B (en) * 2022-05-17 2023-06-23 重庆文理学院 Compound with anti-head and neck cancer effect and preparation method and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (en) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-AMINO-AZOLO (1,5-A) PYRIMIDINE AND FUNGICIDES CONTAINING THEM
KR100191774B1 (en) 1991-04-22 1999-06-15 오스카 아끼히꼬 Pyrazolo(1,5-alpha)pyrimidine derivatives and anti-inflammatory agent containing them
EP0628559B1 (en) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidine compounds and their use as pharmaceuticals
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
CN1046730C (en) 1994-06-21 1999-11-24 株式会社大塚制药工场 Pyrazolo [1,5-a] pyrimidine derivative
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
JP2002501532A (en) 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド Novel angiogenesis inhibitors
ATE355841T1 (en) 1997-12-13 2007-03-15 Bristol Myers Squibb Co USE OF PYRAZOLO (3,4-B)PYRIDINE AS A CYCLINE-DEPENDENT KINASE INHIBITOR
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
JP4876239B2 (en) 1999-01-11 2012-02-15 プリンストン ユニバーシティー High affinity inhibitors for target confirmation and use thereof
FR2805160B1 (en) * 2000-02-23 2002-04-05 Oreal COMPOSITIONS FOR OXIDATION DYEING OF KERATINIC FIBERS COMPRISING N (2-HYDROXYBENZENE) -CARBRAMATE OR N- (2-HYDROXYBENZENE) -UREA AND PYRAZOLOPYRIMIDINE, AND DYEING METHODS
CN100457753C (en) 2000-07-26 2009-02-04 布里斯托尔-迈尔斯斯奎布公司 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
ZA200301696B (en) 2000-09-15 2004-04-28 Vertex Pharma Isoxazoles and their use as inhibitors of erk.
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
JP2002212076A (en) * 2000-11-17 2002-07-31 Ishihara Sangyo Kaisha Ltd Prophylactic or therapeutic agent for diabetes comprising condensed heterocyclic compound or its salt
AU2509602A (en) 2000-12-20 2002-07-01 Sod Conseils Rech Applic Cyclin-dependent kinase (CDK) and glycolene synthase kinase-3 (GSK-3) inhibitors
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
DE10223917A1 (en) 2002-05-29 2003-12-11 Bayer Cropscience Ag New 7-amino-6-aryl-pyrazolo-(1,5-a)-pyrimidine derivatives, useful as pesticides, e.g. insecticides, acaricides, nematocides, bactericides or especially fungicides for protection of plants or materials
WO2003101993A1 (en) 2002-06-04 2003-12-11 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
KR101088922B1 (en) * 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
PE20051089A1 (en) 2004-01-22 2006-01-25 Novartis Ag PYRAZOLE [1,5-A] PYRIMIDIN-7-IL-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
ATE448229T1 (en) * 2005-01-19 2009-11-15 Merck & Co Inc BICYCLIC PYRIMIDINES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
EP1931676B1 (en) * 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors

Also Published As

Publication number Publication date
ECSP088350A (en) 2008-05-30
NO20082092L (en) 2008-07-04
JP2012082233A (en) 2012-04-26
CN101321760A (en) 2008-12-10
JP2009511491A (en) 2009-03-19
JP5052518B2 (en) 2012-10-17
BRPI0617150A2 (en) 2011-07-12
EP1931676B1 (en) 2011-11-16
PE20070543A1 (en) 2007-06-14
US7776865B2 (en) 2010-08-17
TW200745123A (en) 2007-12-16
WO2007041712A1 (en) 2007-04-12
RU2008117298A (en) 2009-11-20
AR056206A1 (en) 2007-09-26
US20070083044A1 (en) 2007-04-12
CA2624882A1 (en) 2007-04-12
ZA200802995B (en) 2009-02-25
IL190598A0 (en) 2008-11-03
KR20080063806A (en) 2008-07-07
EP1931676A1 (en) 2008-06-18
AU2006299338A1 (en) 2007-04-12
CA2624882C (en) 2014-05-20

Similar Documents

Publication Publication Date Title
ATE533770T1 (en) PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS
ATE501142T1 (en) PHENYLACETAMIDE SUITABLE AS PROTEIN KINASE INHIBITORS
IL191294A0 (en) Imidazopyrazines as protein kinase inhibitors
DK1951724T3 (en) Merged bicyclic mTOR inhibitors
DE60314427D1 (en) PYRAZOLOPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES
ATE479434T1 (en) DYHYDRODIAZEPINES USABLE AS PROTEIN KINASE INHIBITORS
DK1973910T3 (en) Pyrrolo [3,2-c] pyridin-4-one-2-indolinone protein kinase inhibitors
DE60317077D1 (en) PYRAZOLOPYRIMIDINES AS INHIBITORS CYCLINE-DEPENDENT KINASES
ATE530545T1 (en) PYRAZOLYLAMINOPYRIDINE DERIVATIVES SUITABLE AS KINASE INHIBITORS
ATE443706T1 (en) PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
DK1720882T3 (en) Pyrazolopyrimidine derivatives as cyclin-dependent kinase inhibitors
ATE518860T1 (en) PYRROLOÄ2,3-BÜPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
ATE523499T1 (en) CYCLOPENTA [D]-PYRIMIDINE AS AN AKT PROTEIN KINASE INHIBITOR
DE602004025258D1 (en) AMINOTRIAZOL COMPOUNDS AS PROTEIN KINASE INHIBITORS
ATE524467T1 (en) NOVEL AZA HETEROCYCLES AS KINASE INHIBITORS
ATE520671T1 (en) PYRIMIDINE-UREA DERIVATIVES AS KINASE INHIBITORS
TWI372625B (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE602005020465D1 (en) ENANTIOMERINEINE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITOR
ATE492544T1 (en) PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS
ATE531705T1 (en) SUBSTITUTED 2-QUINOLYLOXAZOLES SUITABLE AS PDE4 INHIBITORS
DE602005022115D1 (en) HETERO-AROMATIC CHINOLIN COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS
ATE512972T1 (en) PYRROLOPYRAZOLES AS EFFECTIVE KINASE INHIBITORS
HK1124039A1 (en) PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
ZA200709269B (en) Protein kinase inhibitors
ATE478868T1 (en) PYRROLODIHYDROISOCHINOLINES AS PDE10 INHIBITORS